- Submission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EU
- Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that can drastically affect an individual’s everyday life and requires life-long treatment
- Sandoz is committed to accelerating patient access to potentially life-changing, high-quality treatments, while generating savings for healthcare systems and patients
Basel, July 25, 2022 …
- Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study
- Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic immune-mediated inflammatory diseases
- Sandoz is committed to supporting healthcare professionals to advance patient care and improve access to medicines sustainably and affordably
Basel, July 21, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today …
Ad hoc announcement pursuant to Art. 53 LR
- Q2 sales grew +5% cc1 (-1% USD)
- Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33% cc), Kesimpta (+270% cc), Cosentyx (+12% cc), Kisqali (+43% cc) and Zolgensma (+26% cc)
- Sandoz sales grew +5% cc (-3% USD) benefiting from a return towards normal business dynamics, with growth across all business …
- Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study
- Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients
- Submission builds on Sandoz’ well established biosimilar immunology portfolio in Europe
Basel, June 17, 2022 — Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Medicines Agency (EMA) has accepted the application for high concentration …
- Dimethyl fumarate HEXAL® is bioequivalent to the originator product 1,2,3
- Additional 196 pack size reduces co-payment burden for patients
Basel, June 10, 2022 — Sandoz expands its portfolio and today announces the launch of the generic drug Dimethyl fumarate HEXAL®, which is approved for the treatment of adults with relapsing remitting multiple sclerosis (RRMS) 1, in Germany.
“We are proud to introduce a generic drug for German patients for the treatment of …
- Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders
- Action Plan will provide roadmap and tools to improve approvability, accessibility, acceptability and affordability (4As) of biosimilars
- Sandoz launched initiative to support improved healthcare access, equity and sustainability
Basel, May 31, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today …
- Dr. Boumediene Soufi, global head of Sandoz AMR (antimicrobial resistance) program, to represent Sandoz as Board member of AMR Industry Alliance (AMRIA)
- The Alliance brings together about 100 life science companies / associations in search of sustainable solutions to curb AMR
- Sandoz, as largest global provider of generic antibiotics1, is committed to a pragmatic and balanced …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia